CR11273A - Derivados-2-ona disustituidos en 3, su preparacion y su aplicacion en terapeutica - Google Patents

Derivados-2-ona disustituidos en 3, su preparacion y su aplicacion en terapeutica

Info

Publication number
CR11273A
CR11273A CR11273A CR11273A CR11273A CR 11273 A CR11273 A CR 11273A CR 11273 A CR11273 A CR 11273A CR 11273 A CR11273 A CR 11273A CR 11273 A CR11273 A CR 11273A
Authority
CR
Costa Rica
Prior art keywords
disstituted
derivados
ona
therapeutics
preparation
Prior art date
Application number
CR11273A
Other languages
English (en)
Inventor
Marco Baroni
Letizia Puleo
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CR11273A publication Critical patent/CR11273A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion tiene por objetos los derivados de indol-2-ona disustituidos en 3, de formula general (I), en la que, R1, ----, R1, R2, R3, R4, R5, AR y n son tales como se han definido en la reivindicacion 1, el procedimiento de preparacion y la aplicacion terapeutica de dichos compuestos.
CR11273A 2007-08-16 2010-02-12 Derivados-2-ona disustituidos en 3, su preparacion y su aplicacion en terapeutica CR11273A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0705858A FR2920023B1 (fr) 2007-08-16 2007-08-16 Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
CR11273A true CR11273A (es) 2010-07-16

Family

ID=39197313

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11273A CR11273A (es) 2007-08-16 2010-02-12 Derivados-2-ona disustituidos en 3, su preparacion y su aplicacion en terapeutica

Country Status (42)

Country Link
US (2) US20100210662A1 (es)
EP (1) EP2188253B8 (es)
JP (1) JP5685440B2 (es)
KR (1) KR20100051812A (es)
CN (1) CN103443076B (es)
AR (1) AR067937A1 (es)
AT (1) ATE548349T1 (es)
AU (1) AU2008320718B2 (es)
BR (1) BRPI0815171A2 (es)
CA (1) CA2696237C (es)
CO (1) CO6251363A2 (es)
CR (1) CR11273A (es)
CY (1) CY1112809T1 (es)
DK (1) DK2188253T3 (es)
DO (1) DOP2010000050A (es)
EA (1) EA019486B1 (es)
EC (1) ECSP109961A (es)
ES (1) ES2384080T3 (es)
FR (1) FR2920023B1 (es)
GT (1) GT201000032A (es)
HN (1) HN2010000330A (es)
HR (1) HRP20120466T1 (es)
IL (1) IL203956A (es)
JO (1) JO2749B1 (es)
MA (1) MA31742B1 (es)
ME (1) ME00979B (es)
MX (1) MX2010001851A (es)
MY (1) MY149649A (es)
NI (1) NI201000023A (es)
NZ (1) NZ583317A (es)
PA (1) PA8793101A1 (es)
PE (1) PE20090988A1 (es)
PL (1) PL2188253T3 (es)
PT (1) PT2188253E (es)
RS (1) RS52321B (es)
SI (1) SI2188253T1 (es)
TN (1) TN2010000025A1 (es)
TW (1) TWI432423B (es)
UA (1) UA101162C2 (es)
UY (1) UY31297A1 (es)
WO (1) WO2009056707A2 (es)
ZA (1) ZA201001085B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
FR2941946B1 (fr) * 2009-02-12 2011-03-25 Sanofi Aventis Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
FR2941947B1 (fr) * 2009-02-12 2011-03-25 Sanofi Aventis Derives de 3-benzofuranyl-indol-2-one subtitues en 3, leur preparation et leur application en therapeutique
MX339194B (es) 2009-02-13 2016-05-16 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv y opcionalmente otro agente antidiabetico, y usos de la misma.
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
CN108658836B (zh) * 2018-05-15 2021-04-20 宁波大学 一种3-取代-3-叠氮基吲哚-2-酮类化合物的制备方法
EP3912625A1 (en) * 2020-05-20 2021-11-24 Kaerus Bioscience Limited Novel maxi-k potassium channel openers for the treatment of fragile x associated disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2714378B1 (fr) * 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
CN1161333C (zh) * 1998-08-20 2004-08-11 住友制药株式会社 作为生长激素释放剂的2-羟基吲哚衍生物
FR2827604B1 (fr) * 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
JPWO2005035498A1 (ja) * 2003-10-08 2006-12-21 住友製薬株式会社 含窒素二環性化合物の摂食調節剤としての用途

Also Published As

Publication number Publication date
MX2010001851A (es) 2010-03-11
US8202871B2 (en) 2012-06-19
CN103443076B (zh) 2016-06-22
JO2749B1 (en) 2014-03-15
FR2920023A1 (fr) 2009-02-20
FR2920023B1 (fr) 2013-02-08
EP2188253B8 (fr) 2012-04-11
UY31297A1 (es) 2009-03-31
NZ583317A (en) 2011-11-25
US20100210662A1 (en) 2010-08-19
ES2384080T3 (es) 2012-06-29
WO2009056707A2 (fr) 2009-05-07
UA101162C2 (ru) 2013-03-11
WO2009056707A8 (fr) 2010-03-18
PT2188253E (pt) 2012-05-11
MA31742B1 (fr) 2010-10-01
JP5685440B2 (ja) 2015-03-18
PE20090988A1 (es) 2009-08-14
DK2188253T3 (da) 2012-07-02
AU2008320718A1 (en) 2009-05-07
TWI432423B (zh) 2014-04-01
EP2188253B1 (fr) 2012-03-07
HRP20120466T1 (hr) 2012-07-31
HN2010000330A (es) 2012-03-19
US20110118280A1 (en) 2011-05-19
IL203956A (en) 2014-06-30
MY149649A (en) 2013-09-30
ATE548349T1 (de) 2012-03-15
JP2010536736A (ja) 2010-12-02
EA201070281A1 (ru) 2010-08-30
CO6251363A2 (es) 2011-02-21
TN2010000025A1 (fr) 2011-09-26
DOP2010000050A (es) 2010-04-15
RS52321B (sr) 2012-12-31
CN103443076A (zh) 2013-12-11
SI2188253T1 (sl) 2012-09-28
CA2696237C (fr) 2016-07-05
ECSP109961A (es) 2010-03-31
WO2009056707A3 (fr) 2009-10-01
ZA201001085B (en) 2011-04-28
KR20100051812A (ko) 2010-05-18
PA8793101A1 (es) 2009-01-23
NI201000023A (es) 2010-03-11
BRPI0815171A2 (pt) 2015-03-31
ME00979B (me) 2012-06-20
CY1112809T1 (el) 2016-02-10
AR067937A1 (es) 2009-10-28
AU2008320718B2 (en) 2013-09-19
PL2188253T3 (pl) 2012-08-31
EP2188253A2 (fr) 2010-05-26
EA019486B1 (ru) 2014-04-30
CA2696237A1 (fr) 2009-05-07
TW200914438A (en) 2009-04-01
GT201000032A (es) 2012-03-12

Similar Documents

Publication Publication Date Title
ECSP10010722A (es) Compuestos orgánicos
CU20110204A7 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
DOP2011000076A (es) Derivados de heteroaril amidas y su uso como activadores de glucoquinasa
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
CO6741214A2 (es) Composiciones pesticidas y procesos relacionados
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
ECSP12012161A (es) Compuestos en calidad de antagonistas de Bradiquinina-b1
HN2006018410A (es) Nuevos derivados del fluoreno, composiciones que los contienen y utilizacion
ECSP10010058A (es) Derivados de quinazolinadiona, su preparación y sus aplicaciones terapéuticas
HN2010000330A (es) DERIVADOS DE INDOL-2-ONA DISUSTITUIDOS EN 3 y SU PREPARACION
NI201100076A (es) Péptidos antivirales terapéuticos.
CR11157A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
PA8855001A1 (es) Monocarbamas
CO6341625A2 (es) Derivados de indol como agentes anticáncer
CR10548A (es) 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen
GT200500292A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
DOP2006000087A (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
SV2011003839A (es) Agentes antifungicos
DOP2009000214A (es) Macrolidos basados en eritromicina
CR11449A (es) Productos intermedios gsm
UY29631A1 (es) Derivados del 4,5-diarilpirrol, su preparación y su aplicación en terapéutica
UY32447A (es) Derivados de 3-benzofuranilindol-2-ona sustituidos en 3, su preparacion y su aplicacion en terapia
UY32448A (es) Derivados de 3-benzofuranil-indol-2-ona-3-acetamidopiperazinas sustituidos, su preparacion y su aplicacion en terapeutica